Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | KDM5C | P41229 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25165297 | 0.88 | — | — | |
| SCHEMBL30260039 | 0.77 | MEN1 (0.31) | MEN1ALDH1A1KMT2A | |
| SCHEMBL24424957 | 0.77 | MEN1 (0.31) | MEN1ALDH1A1KMT2A | |
| SCHEMBL27094449 | 0.75 | DHODH (0.34) | ALDH1A1 | |
| SCHEMBL22220706 | 0.74 | — | — | |
| SCHEMBL29680399 | 0.74 | — | — | |
| SCHEMBL29876162 | 0.74 | KDM4E (0.31) | KDM4EMEN1ALDH1A1GAAMAPT | |
| SCHEMBL18128716 | 0.74 | KDM4E (0.31) | KDM4EMEN1ALDH1A1GAAMAPT | |
| SCHEMBL25805402 | 0.72 | MEN1 (0.37) | KDM4EMEN1ALDH1A1GAAMAPT | |
| SCHEMBL25095561 | 0.71 | GRIN2D (0.40) | KDM4EMEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406849-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED (CN) | 2023-12-21 | — | — | US | disclosed |
| CN-116867779-A | KRAS inhibitors for cancer treatment | 泰励生物科技（上海）有限公司 | 2023-10-10 | — | — | CN | disclosed |
| EP-4242207-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | Tyligand Bioscience (Shanghai) Limited (CN) | 2023-09-13 | — | — | EP | disclosed |
| EP-4242207-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | Tyligand Bioscience (Shanghai) Limited (CN) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023061294-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 再鼎医药(上海)有限公司 | 2023-04-20 | — | — | WO | disclosed |
| WO-2023061294-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 再鼎医药(上海)有限公司 | 2023-04-20 | — | — | WO | disclosed |
| CN-114920738-A | KRas inhibitors for cancer treatment | 泰励生物科技（上海）有限公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2022095960-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | 泰励生物科技（上海）有限公司 | 2022-05-12 | — | — | WO | disclosed |
| WO-2022095960-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | 泰励生物科技（上海）有限公司 | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406849-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | KRAS, NRAS, HRAS | KDM4E 3593/4885MEN1 226/4885ALDH1A1 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.